Denmark
Genmab, founded in 1999, is a pioneering international biotechnology company headquartered in Denmark. Renowned for its expertise in antibody innovation, Genmab focuses on developing differentiated human antibody therapeutics aimed at treating cancer and other serious diseases. Through its innovative approach, the company has spearheaded advancements in antibody-based formats, including bispecific antibodies and antibody-drug conjugates.
With a strong commitment to transforming science into medicine, Genmab is advancing its robust late-stage clinical pipeline, comprising both wholly owned and partnership programs. This effort is aligned with their slogan, "Differentiated human antibody therapeutics for the treatment of cancer." The company's core values encapsulate passion for innovation, integrity, teamwork, and a commitment to creating a supportive work environment.
As of their latest financial move, Genmab secured a $51.50M post-IPO equity investment on 01 November 2025, marking a significant milestone for the company's growth and its mission to deliver transformative medical solutions globally.
